All Articles

Chronic hepatitis C and metabolic dysfunction-associated steatotic liver disease: converging pathobiology, hepatocarcinogenesis, and clinical implications in the post-SVR era

An immunocompetent model of hepacivirus-associated liver fibrosis and hepatocellular carcinoma

Metabolic memory and immune evasion in MASLD-HCC progression

Advancing immunotherapy and tumor microenvironment research in hepatocellular carcinoma

From gut-liver axis hijacking to intratumoral microbiota establishment: mechanisms and therapeutic opportunities in hepatocellular carcinoma

Pharmacological chemoprevention of hepatocellular carcinoma: hype, hope, or reality?

Relationship between transarterial chemoembolization treatment frequency and prognosis in hepatocellular carcinoma patients

Pseudocirrhosis: pathophysiology, clinical mimics, and its role in hepatocellular carcinoma diagnosis and management

From platforms to pathways: imaging innovation, quantitative biomarkers, and clinical translation in hepatocellular carcinoma

When a hazard ratio is not enough: non-proportional hazards are reshaping the interpretation of phase III trials in hepatocellular carcinoma

Rewiring neurotrophic signaling to escape targeted therapy in hepatocellular carcinoma

Malnutrition in MASLD-related hepatocellular carcinoma: assessment limitations, multidimensional mechanisms, and microbiome-based interventions

Synergistic era: practice and reflection on TACE combined with systemic therapy in hepatocellular carcinoma

Gut microbiota as predictors of immunotherapy response in hepatocellular carcinoma

Hepatocellular carcinoma tumor immune microenvironment: heterogeneity and therapeutic strategies

A systematic review of comparative economic analyses of systemic therapies for hepatocellular carcinoma

Targeting gut microbiota to overcome immunotherapy resistance in hepatocellular carcinoma: from mechanisms to clinical practice

An activated CD8⁺ T cell-based signature stratifies prognosis and suggests differential sensitivity to immune checkpoint inhibitors in hepatocellular carcinoma